Skip to main content
Top
Published in: International Journal of Hematology 3/2009

01-10-2009 | Case Report

Plasma cell leukemia producing monoclonal immunoglobulin E

Authors: Yuzuru Takemura, Masanobu Ikeda, Kahori Kobayashi, Yuji Nakazawa, Yuichi Mori, Toshimi Mitsuishi, Hiroki Ishigame, Fumiko Kameko, Kiyotaka Fujita, Ryo Ichinohasama

Published in: International Journal of Hematology | Issue 3/2009

Login to get access

Abstract

A 78-year-old male with lumbar pain and dim consciousness presented the clinical pictures of plasma cell leukemia (PCL) producing a large amount of monoclonal immunoglobulin E (IgE)/kappa protein. Laboratory investigation demonstrated an elevated serum calcium level and renal dysfunction. Systemic bone X-ray survey disclosed only a solitary osteolytic lesion. Circulating plasma cells demonstrated CD19/CD56 and MPC-1/CD49e/CD45+/−, the latter indicating the immature phenotype of the tumor cells. Bone marrow was occupied with immature, atypical plasma cells, of which cytoplasms were positive for IgE by direct immunofluorescence analysis. Chromosomes revealed a translocation of (11;14)(q13;q32), which is concordant with cyclinD1-protein overexpression by immunohistochemistry. He was treated with dexamethasone and vincristine, which somewhat improved the laboratory findings. He died of tumor progression after 4-month admission. The clinical and biological characteristics of IgE-producing PCL, a very rare type of plasma cell dyscrasia, are discussed, reviewing the past literature.
Literature
1.
2.
go back to reference Hayes MJ, Carey JL, Krauss JC, Hedstrom DL, Gulbranson RL, Keren DF. Low IgE monoclonal gammopathy level in serum highlights 20-yr survival in a case of IgE multiple myeloma. Eur J Haematol. 2007;78:353–7.CrossRefPubMed Hayes MJ, Carey JL, Krauss JC, Hedstrom DL, Gulbranson RL, Keren DF. Low IgE monoclonal gammopathy level in serum highlights 20-yr survival in a case of IgE multiple myeloma. Eur J Haematol. 2007;78:353–7.CrossRefPubMed
3.
go back to reference Wozney JL, Ahmed F, Bayerl MG, Ehmann WC, Talamo G. Skin involvement in immunoglobulin E multiple myeloma. J Clin Oncol. 2009;27:637–8.CrossRefPubMed Wozney JL, Ahmed F, Bayerl MG, Ehmann WC, Talamo G. Skin involvement in immunoglobulin E multiple myeloma. J Clin Oncol. 2009;27:637–8.CrossRefPubMed
4.
go back to reference Lloyd L, Klingberg SL, Kende M, Howell JF, Clague AE. A case of IgE multiple myeloma. Pathology. 2003;35:87–9.PubMed Lloyd L, Klingberg SL, Kende M, Howell JF, Clague AE. A case of IgE multiple myeloma. Pathology. 2003;35:87–9.PubMed
5.
go back to reference Yamagata N, Shimazaki C, Goto H, Hirata T, Ashihara E, Oku N, et al. IgE plasma cell leukemia successfully treated with combination VAD (vincristine, doxorubicin, dexamethasone) and MP (melphalan, prednisolone) followed by interferon-α. Am J Hematol. 1994;45:262–4.CrossRefPubMed Yamagata N, Shimazaki C, Goto H, Hirata T, Ashihara E, Oku N, et al. IgE plasma cell leukemia successfully treated with combination VAD (vincristine, doxorubicin, dexamethasone) and MP (melphalan, prednisolone) followed by interferon-α. Am J Hematol. 1994;45:262–4.CrossRefPubMed
6.
go back to reference Van Camp B, Durie BGM, Spier C, De Waele M, Van Riet I, Vela E, et al. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1, Leu-19). Blood. 1990;76:377–82.PubMed Van Camp B, Durie BGM, Spier C, De Waele M, Van Riet I, Vela E, et al. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1, Leu-19). Blood. 1990;76:377–82.PubMed
7.
go back to reference Kraj M, Sokołowska U, Kopeć-Szlęzak J, Pogłód R, Kruk B, Woźniak J, et al. Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma. Leukemia Lymphoma. 2008;49:298–305.CrossRefPubMed Kraj M, Sokołowska U, Kopeć-Szlęzak J, Pogłód R, Kruk B, Woźniak J, et al. Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma. Leukemia Lymphoma. 2008;49:298–305.CrossRefPubMed
8.
go back to reference Ridley RC, Xiao H, Hata H, Woodliff J, Epstein J, Sanderson RD. Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood. 1993;81:767–74.PubMed Ridley RC, Xiao H, Hata H, Woodliff J, Epstein J, Sanderson RD. Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood. 1993;81:767–74.PubMed
9.
go back to reference Barker HF, Hamilton MS, Ball J, Drew M, Franklin IM. Expression of adhesion molecules LFA-3 and N-CAM on normal and malignant human plasma cells. Br J Haematol. 1992;81:331–5.CrossRefPubMed Barker HF, Hamilton MS, Ball J, Drew M, Franklin IM. Expression of adhesion molecules LFA-3 and N-CAM on normal and malignant human plasma cells. Br J Haematol. 1992;81:331–5.CrossRefPubMed
10.
go back to reference Mahmoud MS, Ishikawa H, Fujii R, Kawano MM. Induction of CD45 expression and proliferation in U-266 myeloma cell line by interleukin-6. Blood. 1998;92:3887–97.PubMed Mahmoud MS, Ishikawa H, Fujii R, Kawano MM. Induction of CD45 expression and proliferation in U-266 myeloma cell line by interleukin-6. Blood. 1998;92:3887–97.PubMed
11.
go back to reference Fujii R, Ishikawa H, Mahmoud MS, Asaoku H, Kawano MM. MPC-1−CD49e− immature myeloma cells include CD45+ subpopulations that can proliferate in response to IL-6 in human myelomas. Br J Haematol. 1999;105:131–40.CrossRefPubMed Fujii R, Ishikawa H, Mahmoud MS, Asaoku H, Kawano MM. MPC-1CD49e immature myeloma cells include CD45+ subpopulations that can proliferate in response to IL-6 in human myelomas. Br J Haematol. 1999;105:131–40.CrossRefPubMed
12.
go back to reference Otsuyama K, Asaoku H, Kawano MM. An increase in MPC-1− and MPC-1−CD45+ immature myeloma cells in the progressive states of bone marrow plasmacytosis: the revised phenotypic classification of monoclonal marrow plasmacytosis (MOMP-2005). Int J Hematol. 2006;83:39–43.CrossRefPubMed Otsuyama K, Asaoku H, Kawano MM. An increase in MPC-1 and MPC-1CD45+ immature myeloma cells in the progressive states of bone marrow plasmacytosis: the revised phenotypic classification of monoclonal marrow plasmacytosis (MOMP-2005). Int J Hematol. 2006;83:39–43.CrossRefPubMed
13.
go back to reference Avet-Loiseau H, Garand R, Lodé L, Harousseau JL, Bataille R. for the Intergroupe Francophone du Myélome. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood. 2003;101:1570–1.CrossRefPubMed Avet-Loiseau H, Garand R, Lodé L, Harousseau JL, Bataille R. for the Intergroupe Francophone du Myélome. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood. 2003;101:1570–1.CrossRefPubMed
14.
go back to reference Gabrea A, Bergsagel PL, Chesi M, Shou Y, Kuehl WM. Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell. Mol Cell. 1999;3:119–23.CrossRefPubMed Gabrea A, Bergsagel PL, Chesi M, Shou Y, Kuehl WM. Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell. Mol Cell. 1999;3:119–23.CrossRefPubMed
15.
go back to reference Pasqualetti P, Festuccia V, Collacciani A, Acitelli P, Casale R. Plasma cell leukemia. A report on 11 patients and review of the literature. Panminerva Med. 1996;38:179–84.PubMed Pasqualetti P, Festuccia V, Collacciani A, Acitelli P, Casale R. Plasma cell leukemia. A report on 11 patients and review of the literature. Panminerva Med. 1996;38:179–84.PubMed
16.
go back to reference Macro M, André I, Comby E, Chèze S, Chapon F, Ballet JJ, et al. IgE multiple myeloma. Leukemia Lymphoma. 1999;32:597–603.CrossRefPubMed Macro M, André I, Comby E, Chèze S, Chapon F, Ballet JJ, et al. IgE multiple myeloma. Leukemia Lymphoma. 1999;32:597–603.CrossRefPubMed
17.
go back to reference Ogawa M, Kochwa S, Smith C, Ishizaka K, McIntyre OR. Clinical aspects of IgE myeloma. N Engl J Med. 1969;281:1217–20.CrossRefPubMed Ogawa M, Kochwa S, Smith C, Ishizaka K, McIntyre OR. Clinical aspects of IgE myeloma. N Engl J Med. 1969;281:1217–20.CrossRefPubMed
18.
go back to reference Yoshitake J, Hiramatsu S, Komatsubara Y, Matsubara T, Fujita T, Akutagawa H, et al. A case of IgE myeloma. Acta Haematol Jpn. 1976;39:862–75. Yoshitake J, Hiramatsu S, Komatsubara Y, Matsubara T, Fujita T, Akutagawa H, et al. A case of IgE myeloma. Acta Haematol Jpn. 1976;39:862–75.
19.
go back to reference Vaerman JP. A new case of IgE myeloma (Des) ending with renal failure. J Clin Lab Immunol. 1979;2:343–8.PubMed Vaerman JP. A new case of IgE myeloma (Des) ending with renal failure. J Clin Lab Immunol. 1979;2:343–8.PubMed
21.
go back to reference Gallango ML, Suinaga R, Ramírez M. IgE pyroglobulinemia in multiple myeloma. Clin Chim Acta. 1988;176:151–6.CrossRefPubMed Gallango ML, Suinaga R, Ramírez M. IgE pyroglobulinemia in multiple myeloma. Clin Chim Acta. 1988;176:151–6.CrossRefPubMed
22.
go back to reference Kairemo KJA, Lindberg M, Prytz M. IgE myeloma: a case presentation and a review of the literature. Scand J Clin Lab Invest. 1999;59:451–6.CrossRefPubMed Kairemo KJA, Lindberg M, Prytz M. IgE myeloma: a case presentation and a review of the literature. Scand J Clin Lab Invest. 1999;59:451–6.CrossRefPubMed
23.
go back to reference García-Sanz R, Orfão A, González M, Tabernero MD, Bladé J, Moro MJ, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood. 1999;93:1032–7.PubMed García-Sanz R, Orfão A, González M, Tabernero MD, Bladé J, Moro MJ, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood. 1999;93:1032–7.PubMed
24.
go back to reference Pellat-Deceunynck C, Barillé S, Jego G, Puthier D, Robillard N, Pineau D, et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia. 1998;12:1977–82.CrossRefPubMed Pellat-Deceunynck C, Barillé S, Jego G, Puthier D, Robillard N, Pineau D, et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia. 1998;12:1977–82.CrossRefPubMed
25.
go back to reference Cha CH, Park CJ, Huh JR, Chi HS, Suh CW, Kang YK. Significant better prognosis for patients with primary plasma cell leukemia than for patients with secondary plasma cell leukemia. Acta Haematol. 2007;118:178–82.CrossRefPubMed Cha CH, Park CJ, Huh JR, Chi HS, Suh CW, Kang YK. Significant better prognosis for patients with primary plasma cell leukemia than for patients with secondary plasma cell leukemia. Acta Haematol. 2007;118:178–82.CrossRefPubMed
26.
go back to reference Abe M, Hiura K, Wilde J, Moriyama K, Hashimoto T, Ozaki S, et al. Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma. Blood. 2002;100:2195–202.PubMed Abe M, Hiura K, Wilde J, Moriyama K, Hashimoto T, Ozaki S, et al. Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma. Blood. 2002;100:2195–202.PubMed
27.
go back to reference Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, Hashimoto T, et al. Osteoclasts enhance myeloma cell growth and survival via cell–cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood. 2004;104:2484–91.CrossRefPubMed Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, Hashimoto T, et al. Osteoclasts enhance myeloma cell growth and survival via cell–cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood. 2004;104:2484–91.CrossRefPubMed
28.
go back to reference Hashimoto T, Abe M, Oshima T, Shibata H, Ozaki S, Inoue D, et al. Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1α and MIP-1β correlates with lytic bone lesions in patients with multiple myeloma. Br J Haematol. 2004;125:38–41.CrossRefPubMed Hashimoto T, Abe M, Oshima T, Shibata H, Ozaki S, Inoue D, et al. Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1α and MIP-1β correlates with lytic bone lesions in patients with multiple myeloma. Br J Haematol. 2004;125:38–41.CrossRefPubMed
Metadata
Title
Plasma cell leukemia producing monoclonal immunoglobulin E
Authors
Yuzuru Takemura
Masanobu Ikeda
Kahori Kobayashi
Yuji Nakazawa
Yuichi Mori
Toshimi Mitsuishi
Hiroki Ishigame
Fumiko Kameko
Kiyotaka Fujita
Ryo Ichinohasama
Publication date
01-10-2009
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 3/2009
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-009-0407-1

Other articles of this Issue 3/2009

International Journal of Hematology 3/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine